270 related items for PubMed ID: 25029428
1. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.
Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A.
Kidney Int; 2015 Jan; 87(1):217-24. PubMed ID: 25029428
[Abstract] [Full Text] [Related]
2. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
[Abstract] [Full Text] [Related]
3. Prolonged versus standard prednisolone therapy for initial episode of idiopathic nephrotic syndrome.
Mishra OP, Thakur N, Mishra RN, Prasad R.
J Nephrol; 2012 May; 25(3):394-400. PubMed ID: 21928226
[Abstract] [Full Text] [Related]
4. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome.
Bagga A, Hari P, Srivastava RN.
Pediatr Nephrol; 1999 Nov; 13(9):824-7. PubMed ID: 10603129
[Abstract] [Full Text] [Related]
5. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation.
Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Deeks JJ, Wheatley K, Ives NJ, PREDNOS Collaborative Group.
BMJ; 2019 May 23; 365():l1800. PubMed ID: 31335316
[Abstract] [Full Text] [Related]
6. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A.
Kidney Int; 2017 Jul 23; 92(1):248-257. PubMed ID: 28318625
[Abstract] [Full Text] [Related]
7. Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.
Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, Abeyagunawardena S, Illangasekera YA, Karunadasa UI, Trompeter RS.
Pediatr Nephrol; 2017 Aug 23; 32(8):1377-1382. PubMed ID: 28341877
[Abstract] [Full Text] [Related]
8. Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse: A Noninferiority Randomized Controlled Trial.
Kainth D, Hari P, Sinha A, Pandey S, Bagga A.
Clin J Am Soc Nephrol; 2021 Feb 08; 16(2):225-232. PubMed ID: 33478976
[Abstract] [Full Text] [Related]
9. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
Yadav M, Sinha A, Khandelwal P, Hari P, Bagga A.
Pediatr Nephrol; 2019 May 08; 34(5):829-835. PubMed ID: 30194663
[Abstract] [Full Text] [Related]
10. Can we predict relapses in children with idiopathic steroid-sensitive nephrotic syndrome?
Mishra OP, Abhinay A, Mishra RN, Prasad R, Pohl M.
J Trop Pediatr; 2013 Oct 08; 59(5):343-9. PubMed ID: 23619602
[Abstract] [Full Text] [Related]
11. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.
Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, van der Heijden AJ, Nauta J.
J Am Soc Nephrol; 2013 Jan 08; 24(1):149-59. PubMed ID: 23274956
[Abstract] [Full Text] [Related]
12. Long versus standard initial prednisolone therapy in children with idiopathic nephrotic syndrome.
Paul SK, Muinuddin G, Jahan S, Begum A, Rahman MH, Hossain MM.
Mymensingh Med J; 2014 Apr 08; 23(2):261-7. PubMed ID: 24858152
[Abstract] [Full Text] [Related]
13. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.
Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K, Japanese Study Group of Kidney Disease in Children.
Kidney Int; 2015 Jan 08; 87(1):225-32. PubMed ID: 25054775
[Abstract] [Full Text] [Related]
14. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial.
Abeyagunawardena AS, Trompeter RS.
Arch Dis Child; 2008 Mar 08; 93(3):226-8. PubMed ID: 17573408
[Abstract] [Full Text] [Related]
15. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
[Abstract] [Full Text] [Related]
16. Zinc supplement in reduction of relapses in children with steroid sensitive nephrotic syndrome.
Sherali AR, Moorani KN, Chishty SH, Khan SI.
J Coll Physicians Surg Pak; 2014 Feb 04; 24(2):110-3. PubMed ID: 24491005
[Abstract] [Full Text] [Related]
17. REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study.
Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar NCAJ, van den Heuvel LPWJ, Schreuder MF.
BMJ Open; 2017 Sep 27; 7(9):e018148. PubMed ID: 28963315
[Abstract] [Full Text] [Related]
18. Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial).
Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, Saito-Oba M, Nozu K, Shima Y, Iijima K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (JSKDC).
BMC Nephrol; 2018 Sep 10; 19(1):223. PubMed ID: 30200895
[Abstract] [Full Text] [Related]
19. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome.
Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, Massella L, Emma F, Niaudet P, Cornelissen EAM, Schurmans T, Raes A, van de Walle J, van Dyck M, Gulati A, Bagga A, Davin JC, all members of the Levamisole Study Group.
Kidney Int; 2018 Feb 10; 93(2):510-518. PubMed ID: 29054532
[Abstract] [Full Text] [Related]
20. Low-dose versus conventional-dose prednisolone for nephrotic syndrome relapses: a randomized controlled non-inferiority trial.
Sheikh S, Mishra K, Kumar M.
Pediatr Nephrol; 2021 Oct 10; 36(10):3143-3150. PubMed ID: 33861375
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
